MedVax Technologies, Inc. to Present at Biotech Showcase 2014

Live Webcast of MedVax's Presentation on January 15, 2014 at 1:45 p.m. PT


Miami, FL -- (SBWIRE) -- 02/26/2014 -- MedVax Technologies, Inc. , a biopharmaceutical company developing and commercializing cancer vaccine immunotherapies, announced today that Robert Brooks, Chief Executive Officer, will be presenting a company overview at the 6th Annual Biotech Showcase investor and partnering conference on Wednesday, January 15, 2014 at 1:45 p.m. Pacific (10:45 a.m. Eastern) at the Parc 55 Wyndham - Union Square, San Francisco, CA.

A live audio webcast of the presentation will be available in the Investor Relations section of the Company's website at A webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.

About MedVax Technologies, Inc.
MedVax Technologies, Inc. ( is a clinical-stage biopharmaceutical company focused on developing cancer vaccine immunotherapies. The Company is developing a platform of peptide vaccines to be a non-toxic alternative to chemotherapy and monoclonal antibody therapy. Our "off-the-shelf" HER-2 Peptide vaccine has completed a 2nd Phase 1 clinical trial in solid tumors, and we are planning a Phase II trial against HER-2+ breast and gastric cancers. We also are developing an autologous P53 dendritic cell vaccine that is currently in Phase II clinical trials in Small Cell Lung Cancer and breast cancers. We plan to combine our P53 dendritic cell vaccine with a checkpoint inhibitor in further clinical trials

Forward Looking Statements
This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential for MedVax’s technology. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Contact Information:

MedVax Technologies, Inc.
Candace Cobos
VP, Business Administration & Public Relations
(305) 371-2301

Source: MedVax Technologies, Inc.